People living with HIV (PLWH) who are hospitalized for COVID-19 are not more likely to die than those without HIV despite having comorbidities associated with worse COVID-19 outcomes, a US study has shown.
Dolutegravir demonstrated noninferiority to low-dose efavirenz in antiretroviral (ART)-naïve patients with HIV-1 infection in a resource-limited setting, according to the NAMSAL ANRS 12313* study presented at IAS 2019.
Children born to women receiving dolutegravir-based antiretroviral therapy (ART) for HIV since conception have an uptick of neural-tube defects compared with those whose mothers took non-dolutegravir ART at conception, additional follow-up data from the Tsepamo surveillance study show.
The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.
The investigational first-in-class attachment inhibitor prodrug fostemsavir (FTR) continues to improve virologic and immunologic response from weeks 48 to 96 in patients with multidrug-resistant HIV-1 who had been heavily treated, according to the BRIGHTE* study presented at IAS 2019.
Individuals with HIV-1 who demonstrate virologic suppression on a tenofovir alafenamide fumarate (TAF)-based three- or four-drug regimen (TBR) could safely switch to a two-drug regimen comprising dolutegravir and lamivudine, according to results from the phase III TANGO* study presented at the recent International AIDS Society conference (IAS 2019).
The guideline-recommended, single-tablet, fixed-dose regimen comprising bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) was noninferior to the dolutegravir and F/TAF (D/F/TAF) regimen in persons living with HIV (PLHIV), according to data presented at IAS 2019.
Persons living with HIV (PLHIV) who received monthly long-acting (LA) intramuscular formulations of the INSTI* cabotegravir and the NNRTI** rilpivirine reported higher levels of treatment satisfaction and treatment acceptance, and greater willingness to continue therapy as opposed to a daily oral antiretroviral therapy (ART) regimen, according to patient-reported outcomes of the ATLAS*** and FLAIR# trials presented at IAS 2019.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.
The use of aspirin for primary prevention in patients without known cardiovascular diseases (CVDs) significantly reduces the risk of myocardial infarction (MI) but increases that of major bleeding and haemorrhagic stroke, according to a meta-analysis.